In this cohort, the burden of pre-existing cerebral small vessel disease indicated by modified Fazekas scale scoring of white matter hyperintensities is significantly different in IL-17B+ subjects compared with IL-17B− subjects (p < 0.0001). Here, IL17B is linked to cerebral small vessel disease.